Clinical Trial Update: FAPI in Rectal Cancer TNT

View source ↗

Summary

A clinical trial testing a fibroblast activation protein inhibitor (FAPI) in rectal cancer using total neoadjuvant therapy is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• FAPI (Fibroblast activation protein inhibitor)

Snippet

Sponsor: Chang Gung Memorial Hospital | Conditions: Rectal Neoplasms Malignant | Status: RECRUITING